Navamedic ASA: Double Digit Growth in the 3rd Quarter, 2025
Navamedic ASA (OSE: NAVA), a Nordic pharma company, reported a 12.9% increase in revenues to NOK 138.9 million in the third quarter of 2025.
The company's gross margin improved to 37.5%, compared to 37.1% in Q3 2024. Adjusted EBITDA amounted to NOK 11.3 million, compared to NOK 8.6 million in 2024.
- Revenues: NOK 138.9 million, a 12.9% increase from Q3 2024
- Gross margin: 37.5%, compared to 37.1% in Q3 2024
- Adjusted EBITDA: NOK 11.3 million, compared to NOK 8.6 million in 2024
The revenue growth was driven by increases in all three business areas, including the Rx business area, which included NOK 10.6 million in revenues from the dne business.
No direct quote available in the text.
Author's summary: Navamedic ASA reports 12.9% revenue growth.